Sigyn Therapeutics, Inc.
SIGY· OTC
SIGYSigyn Therapeutics, Inc.
Filed Nov 19, 2024 · 10-Q · 50 days after period end · 0001493152-24-046847
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Net Income | -$1.20M | -$905.73K | -$726.51K | -$665.90K |
| EPS Diluted | -$0.94 | -$0.82 | -$0.02 | -$0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
ended Sep 30, 2024 · filed Nov 19, 2024 · 50 d after period end
